To develop a split-Cas9 system, we identified 11 potential split sites based on a crystal structure of Cas9 in complex with a single guide RNA (sgRNA) and complementary target DNA 6 (Fig. 1a and Supplementary Fig. 1a) . The resulting C-terminal Cas9 fragment Cas9(C) and N-terminal Cas9 fragment Cas9(N) were fused to FK506 binding protein 12 (FKBP) and FKBP rapamycin binding (FRB) domains 7 of the mammalian target of rapamycin (mTOR), respectively, to make 11 split-Cas9 sets (split-1 through split-11)
A split-Cas9 architecture for inducible genome editing and transcription modulation c o r r e s p o n d e n c e npg Therefore, we generated a lentivirus construct for split-5 (LSC-5 for lentivirus split-Cas9 split-5; Fig. 1f ) and transduced HEK293FT cells with an multiplicity of infection (MOI) of ≤ 0.3 followed by puromycin selection for 5 days.
DNA from wild-type (wt)-Cas9-transduced HEK293FT cells was analyzed by deep sequencing 4 weeks after transduction, whereas DNA from LSC-5-transduced cells was analyzed after 6 weeks, to allow for 12 consecutive days of treatment with 200 nM rapamycin (Fig. 1g) . In cells transduced with a lentivirus carrying both wt-Cas9 and an EMX1-targeting sgRNA, we detected ~95% indel frequency at the on-target site as well as mutations at four validated off-target sites (OT-1, 2, 3 and 4) OT-1 = 2%, OT-2 = 2%, OT-3 0.7% and OT-4 = 38%. In comparison, on-target indel frequency in cells transduced with LSC-5 was ~43% after 12 days of rapamycin treatment. In untreated cells, no significant difference in EMX1 on-target indels could be detected between LSC-5 and control samples. Notably, no significant modification of off-target sites could be detected in cells transduced with LSC-5, regardless of rapamycin treatment (one-way where it is less likely to dimerize with the nuclear-localized Cas9(C)-FKBP fragment, we replaced the two nuclear localization sequences (NLSs) on Cas9(N)-FRB with a single nuclear export sequence (NES) (Cas9(N)-FRB-NES). In the presence of rapamycin, Cas9(N)-FRB-NES dimerizes with Cas9(C)-FKBP-2 × NLS to reconstitute a complete Cas9 protein, which shifts the balance of nuclear trafficking toward nuclear import and allows DNA targeting (Fig. 1c,d) . We tested our strategy with split-4 and split-5 (Fig. 1a) and found that a single NES is sufficient to reduce background activity below the detection limit of the SURVEYOR assay (Fig. 1e) . Our data show that spatial sequestration of Cas9(N)-FRB and Cas9(C)-FKBP split fragments inside the cell, combined with rapamycin-activated dimerization, allows inducible activation of the Cas9 nuclease.
High dosage of Cas9 can exacerbate indel frequencies at off-target sequences 9 . We speculated that induction of low levels of Cas9 activity could be used to reduce off-target indels compared to constitutively active Cas9, which may exhibit high on-target activity but also elevated levels of off-target activity.
( Supplementary Fig. 1b and Fig. 1b) . We tested all split-Cas9 sets by targeting the EMX1 locus in human embryonic kidney 293FT (HEK293FT) cells. Using the SURVEYOR nuclease assay, we detected insertion/deletion (indels) mutations mediated by all split-Cas9 sets in cells treated with rapamycin (Supplementary Methods, for a list of all primers and sgRNAs see Supplementary Tables 2-5 ). In addition, moderate levels of indels could also be detected in the absence of rapamycin (Supplementary Fig. 1c,d) . The observed background activity was not due to residual nuclease activity of individual split pieces (data not shown). Using a small number of split-Cas9 sets lacking dimerization domains, we found that Cas9 split fragments can autoassemble in cells (Supplementary Fig. 1e,g ), which explains our observed background activity.
After establishing that background activity in the split-Cas9 system is due to spontaneous auto-assembly of Cas9, we hypothesized that keeping each Cas9 fragment spatially separated might reduce background activity 8 . To sequester the Cas9(N)-FRB fragment in the cytoplasm, ) strategy for optimizing the split-cas9 system. In the absence of rapamycin (c), the cas9(n)-FrBnes piece is sequestered in the cytoplasm owing to the addition of a nes. The cas9(c)-FKBp piece contains two nLss and is actively imported into the nucleus. In the presence of rapamycin (d), cas9(n)-FrB-nes binds to cas9(c)-FKBp. nLss of the resulting reassembled cas9 mediate nuclear importation and subsequent binding to the targeted locus. (e) representative sUrVeYor assay for split-4-and split-5-mediated indels at the human EMX1 locus, with (left) and without (right) rapamycin. Arrowheads indicate expected sUrVeYor fragments. nd, not detected. (f) schematic of lentiviral split-cas9 plasmid containing U6 promoter-driven sgrnA, eFs promoter-driven split-cas9 pieces and puromycin resistance gene (puro). 2A self-cleaving peptides (p2A) separate both split-cas9 pieces and puro. (g) Indel frequencies measured by deep sequencing at the EMX1 locus and four annotated oT sites. Indels were measured 4 weeks (wt-cas9; n = 2 biological replicates) or 6 weeks (split-cas9; n = 3 biological replicates) after transduction (****P < 0.0001). rapamycin treatments lasted 12 days. Mean ± s.e.m. in all panels. ns, not significant. . Given the persistent activation after rapamycin withdrawal, this system will be useful for experiments where synchronized activation is beneficial, such as cellular differentiation or development or modulation of genes that adversely affect the health or growth of the cell.
Taken together, we have demonstrated that Cas9 can be split into two distinct fragments, which form a functional fulllength Cas9 nuclease when brought back together by chemical induction. The splitCas9 architecture will be useful for a variety of applications. For example, split-Cas9 systems may enable genetic strategies for restricting Cas9 activity to intersections of cell populations by putting each fragment under a different tissue-specific promoter. Additionally, different chemically inducible dimerization domains, such as abscisic acid or gibberellin-sensing domains, may also be employed to generate an array of inducible Cas9 molecules, fused to different modulatory domains, to construct synthetic transcriptional networks. treated with rapamycin 24 h after transfection and maintained in 200 nM rapamycin until harvested for RNA at 48 h after transfection. A significant increase in mRNA levels, compared with untransfected HEK293FT, could be detected using quantitative realtime PCR (qPCR) for all three genes (oneway ANOVA, ASCL1 P < 0.0001, MYOD1 P < 0.0001, IL1RN P < 0.0001) (Fig. 2b  and Supplementary Fig. 2a) . Background activity was low compared with rapamycininduced cells (+rapamycin/-rapamycin ratio: ASCL1 = 57, MYOD1 = 27, IL1RN = 552) and not significant compared with untransfected cells (one-way ANOVA,P > 0.99).
To test whether transcriptional activation is reversible upon withdrawal of rapamycin, we activated Neurog2 expression in N2A cells and ASCL1 in HEK293FT cells (Fig. 2c  and Supplementary Fig. 2b ). Cells were treated with rapamycin 24 h after transfection. Rapamycin was either withdrawn after 2 h or replaced every 24 h for continuous induction. Cells were harvested at 2, 6, 12, 24 and 72 h after rapamycin treatment, and mRNA levels were analyzed by qPCR. Neurog2 and ASCL1 levels increased during the entire study, with ANOVA, P > 0.9999). Transient transfection experiments using the same guide sgRNA and wt-Cas9 performed previously by us and others 10 showed that at a 32-50% on-target mutation rate, frequency of indels at offtarget site OT-4 was 4-20% (Supplementary Table 1 ). Taken together, these data indicate that stable, low-copy expression of split-Cas9 fragments can be used to induce substantial indels at a targeted locus without high mutation at off-target sites.
Next, we sought to explore whether the split-Cas9 architecture can be applied to catalytically inactive Cas9 (dCas9) to mediate inducible transcription activation. We cloned split-4 fragments harboring a D10→A point mutation in the FRB fusion (dCas9(N)-FRB-2 × NES) and an N863→A point mutation in the FKBP fusion and added a VP64 transactivation domain to Cas9(C)-FKBP-2 × NLS (dCas9(C)-FKBP-2 × NES-VP64) (Fig. 2a) . These fragments reconstitute a catalytically inactive Cas9-VP64 fusion (dCas9-VP64).
We tested split dCas9-VP64 by activating ASCL1, MYOD1 or IL1RN transcription in HEK293FT cells, using four previously validated sgRNAs 11 per gene. Cells were 
